Jane Street Group LLC Trims Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Jane Street Group LLC lowered its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 86.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 17,805 shares of the company's stock after selling 109,358 shares during the period. Jane Street Group LLC owned approximately 0.06% of Aerovate Therapeutics worth $37,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AVTE. Deerfield Management Company L.P. Series C purchased a new position in shares of Aerovate Therapeutics in the 2nd quarter worth $2,343,000. GSA Capital Partners LLP boosted its position in Aerovate Therapeutics by 226.8% in the third quarter. GSA Capital Partners LLP now owns 413,795 shares of the company's stock worth $865,000 after purchasing an additional 287,163 shares during the last quarter. State Street Corp boosted its position in Aerovate Therapeutics by 7.7% in the third quarter. State Street Corp now owns 367,468 shares of the company's stock worth $768,000 after purchasing an additional 26,278 shares during the last quarter. FMR LLC grew its stake in shares of Aerovate Therapeutics by 54,095.4% during the 3rd quarter. FMR LLC now owns 82,919 shares of the company's stock valued at $173,000 after purchasing an additional 82,766 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Aerovate Therapeutics during the 2nd quarter valued at about $35,000.

Aerovate Therapeutics Price Performance

Shares of AVTE traded up $0.15 on Friday, reaching $2.58. The company's stock had a trading volume of 249,881 shares, compared to its average volume of 298,416. The stock's 50 day simple moving average is $2.61 and its two-hundred day simple moving average is $2.19. The stock has a market capitalization of $74.51 million, a P/E ratio of -0.86 and a beta of 1.00. Aerovate Therapeutics, Inc. has a 12-month low of $1.25 and a 12-month high of $32.42.

Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.03. Analysts expect that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current year.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.